Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coherus Bio (NQ: CHRS ) 1.390 +0.070 (+5.30%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Coherus Bio < Previous 1 2 3 Next > Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 August 01, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction June 27, 2024 – Transaction aligns with Coherus’ strategic focus on oncology – From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors June 05, 2024 Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference May 30, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting April 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update March 13, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 March 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Completes Divestiture of Ophthalmology Franchise March 04, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Announces New Employment Inducement Grants February 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv February 21, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP February 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal January 22, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium January 18, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces U.S. Launch of LOQTORZI™ January 02, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv December 26, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx December 11, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Announces CFO Transition Plans December 07, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress December 06, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical November 28, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights November 06, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) November 03, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.